関連レポート

出版元：Transparency Market Research  出版元について

発行年：2024年7月

定価：Single User License $5795 Multi User License $8795 Corporate User License $11795

ご請求は円換算（お見積り日TTSレート）となります。

ご予算に応じた各種ご提案も承ります。詳細はお問い合わせください。

納品形態：PDF by Email

当調査レポートは英文 178ページになります。

商品コード：TMR320

当レポートは発行年月に関わらず、受注の都度、最新情報にアップデートしてお届けいたします。ご希望情報の追加等もご相談可能です。

レポート紹介

多嚢胞性卵巣症候群治療薬の世界市場規模は2023年で27億ドル、2034年に43億ドル、市場の平均年成長率は4.6%にて増加する見込みです。

当レポートでは、多嚢胞性卵巣症候群治療薬の市場予測-2034年、各種セグメント別市場分析(薬剤クラス別、流通チャネル別、国地域別、等)、パイプライン分析、主要製品/ブランド分析、主要企業プロフィールなどの情報を盛り込み、概略以下の構成でお届けいたします。

【レポート構成概要】
■多嚢胞性卵巣症候群治療薬の世界市場予測2020-2034年
・市場規模(US$)

■薬剤クラス別、市場-2034年
・経口避妊薬
・抗アンドロゲン剤
・インスリン感受性改善剤
・抗うつ剤
・抗肥満薬
・利尿薬
・その他
※(市場規模US$)　

■流通チャネル別、市場-2034年
・病院薬局
・小売薬局
・オンライン薬局
※(市場規模US$)　

■主要国地域別市場-2034年
北米
・米国、カナダ
欧州
・ドイツ、英国、フランス
・イタリア、スペイン
・その他欧州
アジア太平洋
・日本、中国、インド
・オーストラリア/ニュージーランド
・その他アジア太平洋
中南米
・ブラジル、メキシコ
・その他中南米
中東アフリカ
・GCC諸国、南アフリカ
・その他中東アフリカ
※地域別に各種セグメント別の細分化データ掲載、詳細は目次参照

■市場分析
市場ダイナミクス
パイプライン分析
主要製品/ブランド分析
主要な合併、買収

■多嚢胞性卵巣症候群治療薬の主要企業プロフィール動向
Abbott Laboratories
AstraZeneca plc
Bayer AG
Bristol-Myers Squibb Company
Ferring B.V.
Merck KGaA
Novartis AG
Pfizer Inc.
Sanofi S.A.
Teva Pharmaceutical Industries Ltd.
Amneal Pharmaceuticals, Inc.
Laurus Labs
Zydus Pharmaceuticals (USA) Inc.
（全178頁）

Table of Contents (英文詳細目次）

1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary: Global Polycystic Ovarian Syndrome Treatment Market

4. Market Overview
4.1. Introduction
4.1.1. Product Definition
4.1.2. Industry Evolution/Developments
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Global Polycystic Ovarian Syndrome Treatment Market Analysis and Forecast, 2020-2034

5. Key Insights
5.1. Pipeline Analysis
5.2. Key Product/Brand Analysis
5.3. Key Mergers & Acquisitions
5.4. COVID-19 Pandemic Impact on Industry

6. Global Polycystic Ovarian Syndrome Treatment Market Analysis and Forecast, by Drug Class
6.1. Introduction & Definition
6.2. Key Findings/Developments
6.3. Market Value Forecast, by Drug Class, 2020-2034
6.3.1. Oral Contraceptives
6.3.2. Antiandrogens
6.3.3. Insulin-sensitizing Agent
6.3.4. Antidepressant
6.3.5. Anti-obesity
6.3.6. Diuretics
6.3.7. Others
6.4. Market Attractiveness Analysis, by Drug Class

7. Global Polycystic Ovarian Syndrome Treatment Market Analysis and Forecast, by Distribution Channel
7.1. Introduction & Definition
7.2. Key Findings/Developments
7.3. Market Value Forecast, by Distribution Channel, 2020-2034
7.3.1. Hospital Pharmacies
7.3.2. Retail Pharmacies
7.3.3. Online Pharmacies
7.4. Market Attractiveness Analysis, by Distribution Channel

8. Global Polycystic Ovarian Syndrome Treatment Market Analysis and Forecast, by Region
8.1. Key Findings
8.2. Market Value Forecast, by Region, 2020-2034
8.2.1. North America
8.2.2. Europe
8.2.3. Asia Pacific
8.2.4. Latin America
8.2.5. Middle East & Africa
8.3. Market Attractiveness Analysis, by Region

9. North America Polycystic Ovarian Syndrome Treatment Market Analysis and Forecast
9.1. Introduction
9.2. Key Findings
9.3. Market Value Forecast, by Drug Class, 2020-2034
9.3.1. Oral Contraceptives
9.3.2. Antiandrogens
9.3.3. Insulin-sensitizing Agent
9.3.4. Antidepressant
9.3.5. Anti-obesity
9.3.6. Diuretics
9.3.7. Others
9.4. Market Value Forecast, by Distribution Channel, 2020-2034
9.4.1. Hospital Pharmacies
9.4.2. Retail Pharmacies
9.4.3. Online Pharmacies
9.5. Market Value Forecast, by Country, 2020-2034
9.5.1. U.S.
9.5.2. Canada
9.6. Market Attractiveness Analysis
9.6.1. By Drug Class
9.6.2. By Distribution Channel
9.6.3. By Country

10. Europe Polycystic Ovarian Syndrome Treatment Market Analysis and Forecast
10.1. Introduction
10.2. Key Findings
10.3. Market Value Forecast, by Drug Class, 2020-2034
10.3.1. Oral Contraceptives
10.3.2. Antiandrogens
10.3.3. Insulin-sensitizing Agent
10.3.4. Antidepressant
10.3.5. Anti-obesity
10.3.6. Diuretics
10.3.7. Others
10.4. Market Value Forecast, by Distribution Channel, 2020-2034
10.4.1. Hospital Pharmacies
10.4.2. Retail Pharmacies
10.4.3. Online Pharmacies
10.5. Market Value Forecast, by Country/Sub-region, 2020-2034
10.5.1. Germany
10.5.2. U.K.
10.5.3. France
10.5.4. Italy
10.5.5. Spain
10.5.6. Rest of Europe
10.6. Market Attractiveness Analysis
10.6.1. By Drug Class
10.6.2. By Distribution Channel
10.6.3. By Country/Sub-region

11. Asia Pacific Polycystic Ovarian Syndrome Treatment Market Analysis and Forecast
11.1. Introduction
11.2. Key Findings
11.3. Market Value Forecast, by Drug Class, 2020-2034
11.3.1. Oral Contraceptives
11.3.2. Antiandrogens
11.3.3. Insulin-sensitizing Agent
11.3.4. Antidepressant
11.3.5. Anti-obesity
11.3.6. Diuretics
11.3.7. Others
11.4. Market Value Forecast, by Distribution Channel, 2020-2034
11.4.1. Hospital Pharmacies
11.4.2. Retail Pharmacies
11.4.3. Online Pharmacies
11.5. Market Value Forecast, by Country/Sub-region, 2020-2034
11.5.1. China
11.5.2. Japan
11.5.3. India
11.5.4. Australia & New Zealand
11.5.5. Rest of Asia Pacific
11.6. Market Attractiveness Analysis
11.6.1. By Drug Class
11.6.2. By Distribution Channel
11.6.3. By Country/Sub-region

12. Latin America Polycystic Ovarian Syndrome Treatment Market Analysis and Forecast
12.1. Introduction
12.2. Key Findings
12.3. Market Value Forecast, by Drug Class, 2020-2034
12.3.1. Oral Contraceptives
12.3.2. Antiandrogens
12.3.3. Insulin-sensitizing Agent
12.3.4. Antidepressant
12.3.5. Anti-obesity
12.3.6. Diuretics
12.3.7. Others
12.4. Market Value Forecast, by Distribution Channel, 2020-2034
12.4.1. Hospital Pharmacies
12.4.2. Retail Pharmacies
12.4.3. Online Pharmacies
12.5. Market Value Forecast, by Country/Sub-region, 2020-2034
12.5.1. Brazil
12.5.2. Mexico
12.5.3. Rest of Latin America
12.6. Market Attractiveness Analysis
12.6.1. By Drug Class
12.6.2. By Distribution Channel
12.6.3. By Country/Sub-region

13. Middle East & Africa Polycystic Ovarian Syndrome Treatment Market Analysis and Forecast
13.1. Introduction
13.2. Key Findings
13.3. Market Value Forecast, by Drug Class, 2020-2034
13.3.1. Oral Contraceptives
13.3.2. Antiandrogens
13.3.3. Insulin-sensitizing Agent
13.3.4. Antidepressant
13.3.5. Anti-obesity
13.3.6. Diuretics
13.3.7. Others
13.4. Market Value Forecast, by Distribution Channel, 2020-2034
13.4.1. Hospital Pharmacies
13.4.2. Retail Pharmacies
13.4.3. Online Pharmacies
13.5. Market Value Forecast, by Country/Sub-region, 2020-2034
13.5.1. GCC Countries
13.5.2. South Africa
13.5.3. Rest of Middle East & Africa
13.6. Market Attractiveness Analysis
13.6.1. By Drug Class
13.6.2. By Distribution Channel
13.6.3. By Country/Sub-region

14. Competition Landscape
14.1. Market Player - Competitive Matrix (by Tier and Size of Companies)
14.2. Market Share Analysis, by Company (2023)
14.3. Company Profiles
14.3.1. Abbott Laboratories
14.3.1.1. Company Overview
14.3.1.2. Product Portfolio
14.3.1.3. SWOT Analysis
14.3.1.4. Financial Overview
14.3.1.5. Strategic Overview
14.3.2. AstraZeneca plc
14.3.2.1. Company Overview
14.3.2.2. Product Portfolio
14.3.2.3. SWOT Analysis
14.3.2.4. Financial Overview
14.3.2.5. Strategic Overview
14.3.3. Bayer AG
14.3.3.1. Company Overview
14.3.3.2. Product Portfolio
14.3.3.3. SWOT Analysis
14.3.3.4. Financial Overview
14.3.3.5. Strategic Overview
14.3.4. Bristol-Myers Squibb Company
14.3.4.1. Company Overview
14.3.4.2. Product Portfolio
14.3.4.3. SWOT Analysis
14.3.4.4. Financial Overview
14.3.4.5. Strategic Overview
14.3.5. Ferring B.V.
14.3.5.1. Company Overview
14.3.5.2. Product Portfolio
14.3.5.3. SWOT Analysis
14.3.5.4. Financial Overview
14.3.5.5. Strategic Overview
14.3.6. Merck KGaA
14.3.6.1. Company Overview
14.3.6.2. Product Portfolio
14.3.6.3. SWOT Analysis
14.3.6.4. Financial Overview
14.3.6.5. Strategic Overview
14.3.7. Novartis AG
14.3.7.1. Company Overview
14.3.7.2. Product Portfolio
14.3.7.3. SWOT Analysis
14.3.7.4. Financial Overview
14.3.7.5. Strategic Overview
14.3.8. Pfizer Inc.
14.3.8.1. Company Overview
14.3.8.2. Product Portfolio
14.3.8.3. SWOT Analysis
14.3.8.4. Financial Overview
14.3.8.5. Strategic Overview
14.3.9. Sanofi S.A.
14.3.9.1. Company Overview
14.3.9.2. Product Portfolio
14.3.9.3. SWOT Analysis
14.3.9.4. Financial Overview
14.3.9.5. Strategic Overview
14.3.10. Teva Pharmaceutical Industries Ltd.
14.3.10.1. Company Overview
14.3.10.2. Product Portfolio
14.3.10.3. SWOT Analysis
14.3.10.4. Financial Overview
14.3.10.5. Strategic Overview
14.3.11. Amneal Pharmaceuticals, Inc.
14.3.11.1. Company Overview
14.3.11.2. Product Portfolio
14.3.11.3. SWOT Analysis
14.3.11.4. Financial Overview
14.3.11.5. Strategic Overview
14.3.12. Laurus Labs
14.3.12.1. Company Overview
14.3.12.2. Product Portfolio
14.3.12.3. SWOT Analysis
14.3.12.4. Financial Overview
14.3.12.5. Strategic Overview
14.3.13. Zydus Pharmaceuticals (USA) Inc.
14.3.13.1. Company Overview
14.3.13.2. Product Portfolio
14.3.13.3. SWOT Analysis
14.3.13.4. Financial Overview
14.3.13.5. Strategic Overview

List of Tables

Table 01: Global Polycystic Ovarian Syndrome Treatment Market Size (US$ Bn) Forecast, by Drug Class, 2020-2034

Table 02: Global Polycystic Ovarian Syndrome Treatment Market Size (US$ Bn) Forecast, by Distribution Channel, 2020-2034

Table 03: Global Polycystic Ovarian Syndrome Treatment Market Size (US$ Bn) Forecast, by Region, 2020-2034

Table 04: North America Polycystic Ovarian Syndrome Treatment Market Size (US$ Bn) Forecast, by Country, 2020-2034

Table 05: North America Polycystic Ovarian Syndrome Treatment Market Size (US$ Bn) Forecast, by Drug Class, 2020-2034

Table 06: North America Polycystic Ovarian Syndrome Treatment Market Size (US$ Bn) Forecast, by Distribution Channel, 2020-2034

Table 07: Europe Polycystic Ovarian Syndrome Treatment Market Size (US$ Bn) Forecast, by Country/Sub-region, 2020-2034

Table 08: Europe Polycystic Ovarian Syndrome Treatment Market Size (US$ Bn) Forecast, by Drug Class, 2020-2034

Table 09: Europe Polycystic Ovarian Syndrome Treatment Market Size (US$ Bn) Forecast, by Distribution Channel, 2020-2034

Table 10: Asia Pacific Polycystic Ovarian Syndrome Treatment Market Size (US$ Bn) Forecast, by Country/Sub-region, 2020-2034

Table 11: Asia Pacific Polycystic Ovarian Syndrome Treatment Market Size (US$ Bn) Forecast, by Drug Class, 2020-2034

Table 12: Asia Pacific Polycystic Ovarian Syndrome Treatment Market Size (US$ Bn) Forecast, by Distribution Channel, 2020-2034

Table 13: Latin America Polycystic Ovarian Syndrome Treatment Market Size (US$ Bn) Forecast, by Country/Sub-region, 2020-2034

Table 14: Latin America Polycystic Ovarian Syndrome Treatment Market Size (US$ Bn) Forecast, by Drug Class, 2020-2034

Table 15: Latin America Polycystic Ovarian Syndrome Treatment Market Size (US$ Bn) Forecast, by Distribution Channel, 2020-2034

Table 16: Middle East & Africa Polycystic Ovarian Syndrome Treatment Market Size (US$ Bn) Forecast, by Country/Sub-region, 2020-2034

Table 17: Middle East & Africa Polycystic Ovarian Syndrome Treatment Market Size (US$ Bn) Forecast, by Drug Class, 2020-2034

Table 18: Middle East & Africa Polycystic Ovarian Syndrome Treatment Market Size (US$ Bn) Forecast, by Distribution Channel, 2020-203

List of Figures

Figure 01: Global Polycystic Ovarian Syndrome Treatment Market Size (US$ Bn) and Distribution (%), by Region, 2023 and 2034

Figure 02: Global Polycystic Ovarian Syndrome Treatment Market Revenue (US$ Bn), by Drug Class, 2023

Figure 03: Global Polycystic Ovarian Syndrome Treatment Market Value Share, by Drug Class, 2023

Figure 04: Global Polycystic Ovarian Syndrome Treatment Market Revenue (US$ Bn), by Distribution Channel, 2023

Figure 05: Global Polycystic Ovarian Syndrome Treatment Market Value Share, by Distribution Channel, 2023

Figure 06: Global Polycystic Ovarian Syndrome Treatment Market Value Share, by Region, 2023

Figure 07: Global Polycystic Ovarian Syndrome Treatment Market Value (US$ Bn) Forecast, 2020-2034

Figure 08: Global Polycystic Ovarian Syndrome Treatment Market Value Share Analysis, by Drug Class, 2023 and 2034

Figure 09: Global Polycystic Ovarian Syndrome Treatment Market Attractiveness Analysis, by Drug Class, 2020-2034

Figure 10: Global Polycystic Ovarian Syndrome Treatment Market Value Share Analysis, by Distribution Channel, 2023 and 2034

Figure 11: Global Polycystic Ovarian Syndrome Treatment Market Attractiveness Analysis, by Distribution Channel, 2020-2034

Figure 12: Global Polycystic Ovarian Syndrome Treatment Market Value Share Analysis, by Region, 2023 and 2034

Figure 13: Global Polycystic Ovarian Syndrome Treatment Market Attractiveness Analysis, by Region, 2020-2034

Figure 14: North America Polycystic Ovarian Syndrome Treatment Market Value (US$ Bn) Forecast and Y-o-Y Growth (%), 2020-2034

Figure 15: North America Polycystic Ovarian Syndrome Treatment Market Attractiveness Analysis, by Country, 2020-2034

Figure 16: North America Polycystic Ovarian Syndrome Treatment Market Value Share Analysis, by Country, 2023 and 2034

Figure 17: North America Polycystic Ovarian Syndrome Treatment Market Value Share Analysis, by Drug Class, 2023 and 2034

Figure 18: North America Polycystic Ovarian Syndrome Treatment Market Value Share Analysis, by Distribution Channel, 2023 and 2034

Figure 19: North America Polycystic Ovarian Syndrome Treatment Market Attractiveness Analysis, by Drug Class, 2020-2034

Figure 20: North America Polycystic Ovarian Syndrome Treatment Market Attractiveness Analysis, by Distribution Channel, 2020-2034

Figure 21: Europe Polycystic Ovarian Syndrome Treatment Market Value (US$ Bn) Forecast and Y-o-Y Growth (%), 2020-2034

Figure 22: Europe Polycystic Ovarian Syndrome Treatment Market Attractiveness Analysis, by Country/Sub-region, 2020-2034

Figure 23: Europe Polycystic Ovarian Syndrome Treatment Market Value Share Analysis, by Country/Sub-region, 2023 and 2034

Figure 24: Europe Polycystic Ovarian Syndrome Treatment Market Value Share Analysis, by Drug Class, 2023 and 2034

Figure 25: Europe Polycystic Ovarian Syndrome Treatment Market Value Share Analysis, by Distribution Channel, 2023 and 2034

Figure 26: Europe Polycystic Ovarian Syndrome Treatment Market Attractiveness Analysis, by Drug Class, 2020-2034

Figure 27: Europe Polycystic Ovarian Syndrome Treatment Market Attractiveness Analysis, by Distribution Channel, 2020-2034

Figure 28: Asia Pacific Polycystic Ovarian Syndrome Treatment Market Value (US$ Bn) Forecast and Y-o-Y Growth (%), 2020-2034

Figure 29: Asia Pacific Polycystic Ovarian Syndrome Treatment Market Attractiveness Analysis, by Country/Sub-region, 2020-2034

Figure 30: Asia Pacific Polycystic Ovarian Syndrome Treatment Market Value Share Analysis, by Country/Sub-region, 2023 and 2034

Figure 31: Asia Pacific Polycystic Ovarian Syndrome Treatment Market Value Share Analysis, by Drug Class, 2023 and 2034

Figure 32: Asia Pacific Polycystic Ovarian Syndrome Treatment Market Value Share Analysis, by Distribution Channel, 2023 and 2034

Figure 33: Asia Pacific Polycystic Ovarian Syndrome Treatment Market Attractiveness Analysis, by Drug Class, 2020-2034

Figure 34: Asia Pacific Polycystic Ovarian Syndrome Treatment Market Attractiveness Analysis, by Distribution Channel, 2020-2034

Figure 35: Latin America Polycystic Ovarian Syndrome Treatment Market Value (US$ Bn) Forecast and Y-o-Y Growth (%), 2020-2034

Figure 36: Latin America Polycystic Ovarian Syndrome Treatment Market Attractiveness Analysis, by Country/Sub-region, 2020-2034

Figure 37: Latin America Polycystic Ovarian Syndrome Treatment Market Value Share Analysis, by Country/Sub-region, 2023 and 2034

Figure 38: Latin America Polycystic Ovarian Syndrome Treatment Market Value Share Analysis, by Drug Class, 2023 and 2034

Figure 39: Latin America Polycystic Ovarian Syndrome Treatment Market Value Share Analysis, by Distribution Channel, 2023 and 2034

Figure 40: Latin America Polycystic Ovarian Syndrome Treatment Market Attractiveness Analysis, by Drug Class, 2020-2034

Figure 41: Latin America Polycystic Ovarian Syndrome Treatment Market Attractiveness Analysis, by Distribution Channel, 2020-2034

Figure 42: Middle East & Africa Polycystic Ovarian Syndrome Treatment Market Size (US$ Bn) Forecast and Y-o-Y Growth (%), 2020-2034

Figure 43: Middle East & Africa Polycystic Ovarian Syndrome Treatment Market Attractiveness Analysis, by Country/Sub-region, 2020-2034

Figure 44: Middle East & Africa Polycystic Ovarian Syndrome Treatment Market Value Share Analysis, by Country/Sub-region, 2023 and 2034

Figure 45: Middle East & Africa Polycystic Ovarian Syndrome Treatment Market Value Share Analysis, by Drug Class, 2023 and 2034

Figure 46: Middle East & Africa Polycystic Ovarian Syndrome Treatment Market Value Share Analysis, by Distribution Channel, 2023 and 2034

Figure 47: Middle East & Africa Polycystic Ovarian Syndrome Treatment Market Attractiveness Analysis, by Drug Class, 2020-2034

Figure 48: Middle East & Africa Polycystic Ovarian Syndrome Treatment Market Attractiveness Analysis, by Distribution Channel, 2020-2034

△ 一番上に戻る